tbuckley/cabot-search huggingface dataset:
CHRONIC MYOSITIS FIBROSA: REPORT OF A CASE
Authors: J M STEELE
Journal: Annals of Internal Medicine (1959)

Case Reports1 December 1959CHRONIC MYOSITIS FIBROSA: REPORT OF A CASEJAMES M. STEELE, M.D., F.A.C.P.JAMES M. STEELE, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-51-6-1395 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough acute myositis is one of the conditions most commonly encountered by the physician, the chronic and generalized forms are more unusual. Of these, chronic generalized myositis fibrosa is a distinct rarity. First described in 1895 by Janicke,1 in 1951 Stewart and Macgregor2 could find only 11 authenticated cases, to which they added a twelfth.The disease is insidious in onset, beginning most frequently in the lower extremities. Stiffness and clumsiness are usually the first complaints, without pain, fever or other signs of constitutional "illness." Induration of the affected muscles spreads until the whole muscle belly becomes involved. This progresses...Bibliography1. Janicke O: Myositis interstitialis, Deutsche med. Wchnschr. 21: 117, 1895, as cited by Schwab et al.3 Google Scholar2. StewartMacgregor AMAR: Myositis fibrosa generalisata, Arch. Dis. Childhood 26: 215-223, 1951. CrossrefMedlineGoogle Scholar3. SchwabBrindleyBodanskyHarris EHPMTH: Generalized myositis fibrosa, Ann. Int. Med. 6: 422-434, 1932. LinkGoogle Scholar4. Somers DC: Generalized myositis fibrosa; report of case, J. Bone and Joint Surg. 21: 414-420, 1939. Google Scholar5. Ornsteen AM: Chronic generalized fibromyositis, Ann. Surg. 101: 237-245, 1935. CrossrefMedlineGoogle Scholar6. BurtonCowanFleming JAJMJ: Generalized myositis fibrosa, Quart. J. Med. 24: 369-370, 1931. CrossrefGoogle Scholar7. Blau A: Primary generalized myositis fibrosa; report of 2 cases with histopathology, J. Mt. Sinai Hosp. 5: 432-443, 1938. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Sayre, Pennsylvania*Received for publication August 18, 1958.Requests for reprints should be addressed to James M. Steele, M.D., Guthrie Clinic Sayre, Pennsylvania. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPain in the Extremities, Dysesthesia, Polyalgia 1 December 1959Volume 51, Issue 6Page: 1395-1400KeywordsArthritisC-reactive proteinsExcretionFeversFibrosisMusclesMyositisStiffness ePublished: 1 December 2008 Issue Published: 1 December 1959 PDF downloadLoading ...
T-cell and antibody responses to phospholipase A2 from different species show distinct cross-reactivity patterns
Authors: B. A. Sin, M. Akdis, J. Zumkehr, S. Bezzine, C. Bekpen, G. Lambeau, C. A. Akdis
Journal: Allergy (2011)

To cite this article: Sin BA, Akdis M, Zumkehr J, Bezzine S, Bekpen C, Lambeau G, Akdis CA. T-cell and antibody responses to phospholipase A2 from different species show distinct cross-reactivity patterns. Allergy 2011; 66: 1513–1521. Background: Secreted phospholipases A2 (sPLA2) represent antigens to which humans may be rarely or frequently exposed. Thus, the investigation of humoral and cellular immune responses to sPLA2s from different species can provide a suitable model in the study of antibody and T-cell cross-reactivity. Methods: Specific IgE, IgG1, IgG4, and IgA antibodies were analyzed by ELISA against sPLA2s from pancreas of Bos taurus (BT), Apis mellifera (AM) bee venom, Daboia russellii (DR) and Naja mossambica (NM) snake venoms, and human group III (hGIII) sPLA2 using sera of nonallergic beekeepers, AM-allergic patients, and healthy controls. T-cell cross-reactivity was investigated in PBMC, and T-cell clones (TCC) are generated against AM sPLA2. Results: Hyperimmune and allergic individuals showed high levels of sPLA2-specific IgG4 and significant IgG4 cross-reactivity between BT, DR, and NM sPLA2s. Furthermore, IgE, IgA, and IgG1 cross-reactivities against BT, DR, and NM sPLA2s were also detectable in the range of 22.2–44.8%. Allergic patients showed significant T-cell proliferative response to NM sPLA2 together with increased IFN-γ and IL-13 production even though they had never been exposed to cobra venom. Although nonallergic healthy controls show no cross-reactivity at T-cell level, they did have low levels of IgG4 and IgA against BT, DR, and NM sPLA2s. Human TCC spanning three major T-cell epitopes of AM sPLA2 showed minor proliferative response to NM and hGIII sPLA2s. Conclusions: This study shows that T cells and antibodies may show cross-reactivity between different species without being naturally exposed to sPLA2s.
Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase
Authors: Irene Rappold, Benedikt L. Ziegler, Iris Köhler, Sylvie Marchetto, Olivier Rosnet, Daniel Birnbaum, Paul J. Simmons, Andrew C W Zannettino, Beth Hill, Stefan Neu, Walter Knapp, Riitta Alitalo, Kari Alitalo, Axel Ullrich, Lothar Kanz, Hans Jörg Bühring
Journal: Blood (1997)
In vitro effects of polycyclic aromatic hydrocarbons and organic extracts from urban air particles on oxidative damage of macromolecules
Authors: Pavel Rossner, Katerina Hanzalova, Radim Sram
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

3129 

The exposure to ambient air pollution has negative health consequences including increased morbidity and mortality. Among other pollutants, ambient air contains particulate matter (PM). PM consists of dust, soot and other particles and various chemicals, including polycyclic aromatic hydrocarbons (PAHs). To investigate the role of PAHs and PM in oxidative stress induction we analyzed oxidative damage to DNA, lipids and proteins in human hepatoma cell line HepG2. Cells were exposed to several concentrations of individual carcinogenic PAHs (cPAHs, including benzo[a]pyrene (B[a]P), dibenzo[al]pyrene (DB[al]P), benzo[a]anthracene (B[a]A), benzo[b]fluoranthene (B[b]F), benzo[k]fluoranthene (B[k]F), chrysene, benzo[ghi]perylene (B[ghi]P), indeno[cd]pyrene (I[cd]P) and dibenzo[ah]anthracene (DB[ah]A)), an artificial mixture of cPAHs (cPAHs mix) and to organic extracts obtained from PM10 (PM < 10 µm) collected by high volume air samplers in summer 2001, winter 2001 and winter 2005 in Prague, Czech Republic. As biomarkers of oxidative stress, 8-oxodeoxyguanosine (8-oxodG), 15-F2t-isoprostane (IsoP) and protein carbonyl levels were measured. All markers were analyzed by ELISA-based assays. Results: Organic extracts induced oxidative damage to DNA and lipids, with the exception of the lowest tested concentration of the summer 2001 extract. However, we observed no effect on oxidative damage to proteins. Individual c-PAHs and c-PAHs mix had mostly no effect on oxidative stress markers; we only found increased 8-oxodG levels after exposure of cells to I[cd]P and DB[ah]A. Interestingly, some of the tested chemicals decreased levels of oxidative stress markers: B[a]P and DB[al]P decreased both protein carbonyl and IsoP levels; cPAHs mix decreased protein carbonyls; chrysene decreased IsoP levels. Conclusions: The results of our study demonstrate the capability of organic extracts obtained from PM10 to induce oxidative damage to DNA and lipids. Our data indicates that cPAHs are not chemical compounds responsible for this activity. It is not clear why organic extracts have no effect on oxidative damage to proteins, as well as why the exposure to some cPAHs decreased levels of oxidative stress markers.    Supported by the Czech Ministry of Environment VaV-SL/5/160/05.
Effect of ebosin on modulating interleukin-1β-induced inflammatory responses in rat fibroblast-like synoviocytes
Authors: Yang Zhang, Lifei Wang, Liping Bai, Rong Jiang, Lianhong Guo, Jianbo Wu, Guifang Cheng, Ren Zhang, Yuan Li
Journal: Cellular and Molecular Immunology (2015)
4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New-Generation Drug-Eluting Stents
Authors: Masanori Taniwaki, Giulio G. Stefanini, Sigmund Silber, Gert Richardt, Pascal Vranckx, Patrick W. Serruys, Pawel E. Buszman, Henning Kelbaek, Stephan Windecker
Journal: Journal of the American College of Cardiology (2014)
Abstract P6-12-05: Inducible suppression of insulin receptor substrate I inhibits IGF-I/insulin/estradiol dependent cell growth in MCF-7L breast cancer cells
Authors: Xihong Zhang, Sidhant Varma, Douglas Yee
Journal: Cancer Research (2015)

Abstract Insulin receptor substrate (IRS) proteins are adaptor proteins downstream of insulin-like growth factor (IGF) and insulin receptors. IRS proteins play a role in cancer biology, with IRS1 function linked to mitogenesis and survival and IRS2 associated with metastasis. Moreover, this family of adaptor proteins is also involved in the signal transduction of many other transmembrane receptors. Therefore IRS proteins could be potential therapeutic targets for cancer therapy. To test the function of IRS-1, we created a doxycycline inducible IRS1 shRNA and stably transfected MCF-7L breast cancer cells. The level of IRS1 protein knockdown varied within different clones from 50 to 95% reduction compared to non-induced cells. IRS2 mRNA and protein levels were not significantly affected. We chose a high (3G5) and intermediate (3A7) IRS1 knockdown clones for further study. Doxycycline treated 3G5 and 3A7, showed partial inhibition of IGF-I, IGF-II and insulin stimulated phosphorylation of IRS1(Tyr1222) and AKT. pErk1,2 were slightly increased and pIGF-IR was unchanged compared to doxycycline non-treated cells. IRS-2 tyrosine phosphorylation was stimulated when IRS-1 was suppressed and may account for the persistent downstream cell signaling. Anti IGFIR antibody dalotuzumab (20µg/ml) effectively inhibited cell signaling stimulated by IGF-I, IGF-II and insulin in both doxycycline treated and non-treated cells. There was no obvious difference in cell signaling pattern between plus and minus doxycycline treated cells within 24 hour time course. In monolayer cell growth assays, IGF-I, IGF-II, insulin and estradiol growth stimulation were significantly inhibited when IRS-1 was suppressed in 3G5 cells. In 3A7 cells, which have a lower level of IRS-1 suppression, growth stimulation was moderately inhibited. In anchorage independent growth assays stimulated by IGF-I, colony number and size were inhibited by doxycycline-induced IRS-1 suppression with a reduction of 80% in 3G5 cells and 50% reduction in 3A7 cells. These results show that growth of MCF-7L cells are dependent on IRS-1 expression. Reduced IRS1 can hinder cancer cell growth and tumorigenicity even when signaling was not impaired potentially due to compensation by other adaptor proteins. We conclude that suppression of IRS-1 may inhibit several growth regulatory pathways in breast cancer and could serve as a potential drug target. Citation Format: Xihong Zhang, Sidhant Varma, Douglas Yee. Inducible suppression of insulin receptor substrate I inhibits IGF-I/insulin/estradiol dependent cell growth in MCF-7L breast cancer cells [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-12-05.
New Orleans: Ragging Home
Authors: M. Therese Southgate
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 15360: Prolonged P Wave Duration is Not Associated With New Onset Atrial Fibrillation During 10-year Follow-up After First-ever Ischemic Stroke in Lund Stroke Register
Authors: Maria A Baturova, Arne Lindgren, Jonas Carlson, Yuri V Shubik, Bertil Olsson, Pyotr G Platonov
Journal: Circulation (2014)

Introduction: Prolonged P-wave duration (PWD) is associated with paroxysmal atrial fibrillation (AF), which might be underdiagnosed in ischemic stroke patients, in whom it might be pivotal for initiation of secondary prevention oral anticoagulation therapy. We aimed to assess whether PWD predicts new-onset AF during 10-year follow-up in ischemic stroke patients compared to control subjects enrolled in the Lund Stroke Register (LSR). Methods: Study sample comprised of 227 first-ever ischemic stroke patients without AF (mean age 72±12 y, 92 female) and 1:1 age- and gender- matched control subjects without stroke and AF enrolled in LSR from Mar 2001 to Feb 2002. The date of new-onset AF during follow-up was assessed by the date of first AF ECG in the regional ECG database and by record linkage with the Swedish National Patient Register. The available standard snapshot 12-lead sinus rhythm ECGs at baseline were retrieved from electronic database and digitally processed. Results: Patients with ischemic stroke compared to controls more often had hypertension (57% vs 31%), diabetes (15% vs 7%) and vascular diseases (42% vs 13%, all p &lt; 0.005). New-onset AF was detected in 39 (17%) stroke patients and in 30 (13%) controls, p=0.296. In the multivariate Cox regression analysis, new onset AF in the stroke group was associated with age&gt;65 years (HR=3.78, 95%CI 1.32-10.85, p=0.013) and hypertension (HR=2.42, 95%CI 1.09-5.40, p=0.030), but not with PWD. On the contrary, PWD&gt;120 ms was the only independent predictor of new onset AF in the control group after adjustment for age and cardiovascular risk factors (HR=3.36, 95%CI 1.41-8.01, p=0.006, Figure 1). Conclusions: Prolonged P-wave duration is the strongest predictor of AF incidence during 10-year follow-up in stroke-free population. However, in ischemic stroke patients the developing of AF is more likely associated with more advanced cardiovascular comorbidities than with electrical abnormalities in the heart.
The Rho-GTPase binding protein IQGAP2 is required for the glomerular filtration barrier
Authors: Yuya Sugano, Maja T. Lindenmeyer, Ines Auberger, Urs Ziegler, Stephan Segerer, Clemens D. Cohen, Stephan C.F. Neuhauss, Johannes Loffing
Journal: Kidney International (2015)
Program for Research on the Biology of Human Cancer&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: C. C. Little
Journal: JNCI Journal of the National Cancer Institute (1941)

Program for Research on the Biology of Human Cancer Get access C. C. Little C. C. Little Director Roscoe B. Jackson Memorial Laboratory Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 2, Issue 2, October 1941, Pages 133–137, https://doi.org/10.1093/jnci/2.2.133 Published: 01 October 1941
Abstract 3704: Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations
Authors: Maria R. Girotti, Filipa Lopes, Natasha Preece, Dan Niculescu-Duvaz, Alfonso Zambon, Lawrence Davies, Steven Whittaker, Grazia Saturno, Amaya Viros, Malin Pedersen, Bart MJM Suijkerbuijk, Delphine Menard, Robert Mcleary, Louise Johnson, Laura Fish, Sarah Ejiama, Berta Sanchez-Laorden, Neil Carragher, Kenneth Macleod, Garry Ashton, Anna Marusiak, Alberto Fusi, John Brognard, Margaret Frame, Paul Lorigan, Caroline J. Springer, Richard Marais
Journal: Cancer Research (2014)

Abstract The protein kinase BRAF is mutated ∼40% of human melanomas. BRAF is a component of the RAS/RAF/MEK/ERK pathway and BRAF or MEK inhibitors increase progression-free and overall survival in melanoma patients with BRAF mutations. However, most patients relapse with acquired resistance and ∼20% of patients present intrinsic resistance and do not respond to these drugs. We describe here two novel compounds that target mutant BRAF and wild-type CRAF. Our compounds inhibited the growth of melanoma cells that were resistant to BRAF-selective inhibitors. ERK pathway reactivation is responsible for resistance to BRAF targeted therapies in ∼60% of the patients and in ∼25% of patients resistance is driven by acquisition of mutations in NRAS. We show that our compounds inhibited the growth of melanoma cells that were resistant to BRAF-selective inhibitors due to pathway reactivation mediated by different mechanisms. We show that the drugs were active against patient derived xenografts (PDXs) from patients with acquired or intrinsic resistance to BRAF-selective inhibitors and in whose tumors resistance was associated with ERK pathway reactivation. Further, our compounds are active in a PDX from a patient whose tumor developed acquired resistance to a combination of a BRAF-selective plus a MEK inhibitor and associated with acquisition of an NRAS mutation. Thus, our panRAF inhibitors can inhibit melanomas with different mechanisms of acquired or intrinsic resistance to BRAF-selective and BRAF-selective/MEK inhibitor combinations, potentially providing first-line treatment for naïve patients and second-line treatments for a range of relapsed patients. Citation Format: Maria R. Girotti, Filipa Lopes, Natasha Preece, Dan Niculescu-Duvaz, Alfonso Zambon, Lawrence Davies, Steven Whittaker, Grazia Saturno, Amaya Viros, Malin Pedersen, Bart MJM Suijkerbuijk, Delphine Menard, Robert Mcleary, Louise Johnson, Laura Fish, Sarah Ejiama, Berta Sanchez-Laorden, Neil Carragher, Kenneth Macleod, Garry Ashton, Anna Marusiak, Alberto Fusi, John Brognard, Margaret Frame, Paul Lorigan, Caroline J. Springer, Richard Marais. Novel panRAF inhibitors active in melanomas that are resistant to BRAF-selective, or BRAF-selective/MEK inhibitor combinations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3704. doi:10.1158/1538-7445.AM2014-3704
Safety of percutaneous endoscopic gastrotomy under sedation with propofol in patients with amyotrophic lateral sclerosis
Authors: Werner Strobel, Kathi Schweikert, Nora Schaub
Journal: European Respiratory Journal (2011)

Percutaneous endoscopic gastrotomy (PEG) is believed to prolong life and increase quality of life in patients with amyotrophic lateral sclerosis (ALS). Since many ALS patients suffer from respiratory failure and the PEG procedure requires sedation, this intervention is believed to be hazardous.

Methods: We reviewed the charts of all ALS patients who underwent PEG placement in our institution between 2006 and 2010 and collected relevant data on the PEG placement procedure.

Results: 21 patients were identified. All patients had a restrictive pattern in lung function tests (VC 50±9% predicted). Sniff nasal inspiratory pressure was decreased (29±4 cmH2O), daytime blood gases showed hyperkapnia in the majority of patients (mean daytime PaCO2 6.5±0.6 KPa). PEG was performed by two experienced gastroenterologists using the “pull through method”. Oxygen was delivered with a target saturation of 92%. Conscious sedation was reached by bolus administration of propofol. PEG placement could be performed successfully in all patients. Adverse events requiring noninvasive or invasive ventilation were not observed.

Compared to a control group of patients without ALS, ALS patients received lower doses of propofol (157±28 vs. 203±57 mg, p = 0.01) and oxygen (2.0±0.4 vs. 2.9±0.9 l/min, p = 0.02), and the nadir of oxygen saturation was higher in the ALS group (91±2 vs. 88±4%, p = 0.02).

Conclusions: PEG placement under propofol sedation in patients with ALS is safe and acute respiratory complications are rare. Compared with controls the decrease of oxygen saturation during the procedure is lower. This is probably due to a more cautious dosing of propofol.
Validation of a hypertussive model of cough in the rabbit
Authors: Emlyn Clay, Domenico Spina, Clive Page
Journal: European Respiratory Journal (2013)

Background  Potential anti-tussive agents are usually evaluated in naive guinea-pigs, however, the clinical translation is poor. Animal models which demonstrate hypertussive responses have not been exploited in drug development programmes.   Aim  To establish the effect of ozone on the citric acid provoked cough response in the rabbit and to evaluated whether the anti-cholinergic drug, tiotropium bromide is anti-tussive in this model.   Method  Thirty, juvenile male New Zealand Rabbits were studied using whole body plethysmography and a microphone. Rabbits were screened on day 1 and then assessed in a individually controlled 2x2 randomised protocol each 7 days. 3 hours before each experiment rabbits were pre-treated with either nebulised tiotropium bromide (250µM) or vehicle (saline) at 3L.min-1 for 10 mins. One hour before each experiment the rabbits were exposed to either air or ozone (2ppm) at 3L.min-1. During the experiment, rabbits acclimatized for 5mins before being exposed to 10 minutes of nebulised citric acid at either 0.4M or 0.8M.   Results  Acute ozone exposure sensitised rabbits into a hypertussive state in a dose dependent manner from 1.38 ±1.02 to 6.26 ±1.59 in the 0.4M citric acid group (control vs ozone, n = 8) and 0.13 ±0.13 to 8.63 ±1.71 in the 0.8M citric acid group (control vs ozone, n = 8). Tiotropium bromide did not attenuate the cough response in the ozone sensitised rabbit (9.63 ±3.39, n = 8) when compared to the control group (0.51 ±0.26, n = 8).   Conclusion  We have demonstrated that rabbits are relatively refractory to citric acid, however, cough number can be significantly increased following exposure to ozone. Under these conditions we found no evidence of an anti-tussive effect by tiotropium bromide.